规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
1mg |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
Bosutinib (SKI-606) 的 IC50 值在低纳摩尔范围内,是多种慢性粒细胞白血病细胞系中 Bcr-Abl 的有效抑制剂[2]。
|
---|---|
体内研究 (In Vivo) |
在裸鼠中,布舒替尼(口服管饲;75 mg/kg,每日两次或 150 mg/kg,每日一次)具有抗人 KU812 异种移植物作用。伯舒替尼(150 mg/kg;每天一次,每周五天)具有针对同基因 Bcr-Abl WT 和突变 Ba/F3 异种移植物的活性[2]。
|
细胞实验 |
细胞增殖测定[2]
细胞类型:白血病 Bcr-Abl+ 细胞系(KCL22、K562、KU812 和 Lama84) 测试浓度: 0.1 μmol/L 孵育时间: 72 小时 实验结果: 抑制多种人 CML 衍生细胞系,IC50 值范围为 1 至 20 nmol/L |
动物实验 |
Animal/Disease Models: KU812CM L xenograft model[2]
Doses: 75 mg/kg twice (two times) daily or 150 mg/kg one time/day Route of Administration: Bosutinib (po (oral gavage); 75 mg/kg twice (two times) daily or 150 mg/kg one time/day) Experimental Results: Had the therapeutic activity and produced a dose- and schedule-dependent weight loss. Animal/Disease Models: Syngeneic Bcr-Abl WT and mutant Ba/F3 xenografts[2] Doses: 150 mg/kg Route of Administration: Bosutinib (150 mg/kg; one time/day, 5 days weekly) Experimental Results: diminished the rate of tumor growth and prolonged event-free survival of mice. |
参考文献 |
[1]. Jorge E Cortes, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 1;30(28):3486-92.
[2]. Miriam Puttini, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006 Dec 1;66(23):11314-22. |
分子式 |
C26H29CL2N5O3
|
---|---|
分子量 |
530.45
|
CAS号 |
380843-75-4
|
相关CAS号 |
Bosutinib hydrate;918639-08-4;Bosutinib-d8;Bosutinib isomer;1391063-17-4
|
SMILES |
N#CC1=C(NC2=CC(OC)=C(Cl)C=C2Cl)C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=C1
|
InChi Key |
UBPYILGKFZZVDX-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
|
化学名 |
4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
|
别名 |
Bosutinib; SKI606; SKI 606; SK-I606; trade name: Bosulif.
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2% DMSO+30% PEG 300+5% Tween 80+ddH2O: 10 mg/mL 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8852 mL | 9.4260 mL | 18.8519 mL | |
5 mM | 0.3770 mL | 1.8852 mL | 3.7704 mL | |
10 mM | 0.1885 mL | 0.9426 mL | 1.8852 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04793399 | Terminated Has Results | Drug: Bosutinib 400 MG Monotherapy | Chronic Phase-Chronic Myeloid Leukemia |
Fundacion Espanola para la Curacionde la Leucemia Mieloide Cronica |
February 24, 2021 | Phase 1 Phase 2 |
NCT03888222 | Completed | Drug: Placebo Oral Tablet Drug: Bosutinib Oral Tablet |
Dementia With Lewy Bodies | Georgetown University | April 23, 2019 | Phase 2 |
NCT05363488 | Completed | Drug: Bosutinib | Myeloid Leukemia | Pfizer | October 8, 2021 | |
NCT04549480 | Completed | Drug: Bosutinib capsule Drug: Bosutinib tablet |
Healthy Participants | Pfizer | September 16, 2020 | Phase 1 |
SKI-606 is a potent inhibitor of CML cell proliferation and survival.Cancer Res.2003 Jan 15;63(2):375-81. td> |
SKI-606 inhibits tyrosine phosphorylation of cellular proteins and Bcr-Abl in CML cells.Cancer Res.2003 Jan 15;63(2):375-81. td> |
SKI-606 is an Abl kinase inhibitor.Cancer Res.2003 Jan 15;63(2):375-81. td> |
Comparison of inhibition of Bcr-Abl tyrosine phosphorylation and v-Abl phosphorylation by SKI-606.Cancer Res.2003 Jan 15;63(2):375-81. td> |
SKI-606 inhibits downstream signaling from Bcr-Abl.Cancer Res.2003 Jan 15;63(2):375-81. td> |
SKI-606 reduces phosphorylation of Tyr397 in Lyn.Cancer Res.2003 Jan 15;63(2):375-81. td> |